Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3205-3212

  Biftu, Tesfaye ^a   Sinha Roy, Ranabir ^a   Chen, Ping ^a   Qian, Xiaoxia ^a   Feng, Dennis ^a   Kuethe, Jeffrey T ^a   Scapin, Giovanna ^a   Gao, Ying Duo ^a   Yan, Youwei ^a   Krueger, Davida ^a   Bak, Annette ^a   Eiermann, George ^a   He, Jiafang ^a   Cox, Jason ^a   Hicks, Jacqueline ^a   Lyons, Kathy ^a   He, Huaibing ^a   Salituro, Gino ^a   Tong, Sharon ^a   Patel, Sangita ^a   Doss, George ^a   Petrov, Aleksandr ^a   Wu, Joseph ^a   Xu, Shiyao Sherrie ^a   Sewall, Charles ^a   Zhang, Xiaoping ^a   Zhang, Bei ^a   Thornberry, Nancy A ^a   Weber, Ann E ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [7-37] AMIDE; GLUCOSE; HEMOGLOBIN A1C; LONG ACTING DRUG; OMARIGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; BLOOD SAMPLING; CANINE MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHASE 3 CLINICAL TRIAL; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RAT; STEADY STATE; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYPOGLYCEMIC AGENTS; PYRANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899522115     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401992e     Document Type: Article

References (20)

1. IDF Diabetes Atlas, 6 th ed.; International Diabetes Federation: Brussels, Belgium, 2013; http://www.idf.org/diabetesatlas/5e/the-global-burden.
2. Holst, J. J.; Vilsboll, T.; Deacon, C. F. The incretin system and its role in type 2 diabetes mellitus Mol. Cell. Endocrinol. 2009, 297, 127-136
3. Brubaker, P. L. Update on incretin biology: focus on glucagon-like peptide-1 Endocrinology 2010, 151, 1984-1989
4. Havale, S. H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg. Med. Chem. 2009, 17, 1783-1802
5. Leiting, B.; Pryor, K. A.; Wu, J. K.; Marsilio, F.; Patel, R. A.; Craik, C. S.; Ellman, J. A.; Cummings, R. T.; Thornberry, N. A. Catalytic properties and inhibition of proline-specific dipeptidylpeptidases II, IV and VII Biochem. J. 2003, 371, 525-532
6. Evans, D. M. Dipeptidyl peptidase IV inhibitors Drugs 2002, 5, 577-585
7. Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes J. Med. Chem. 2004, 47, 4135-4141
8. Cramer, J. A. A systematic review of adherence with medications for diabetes J. Diabetes Care 2004, 27, 1218-1224
9. Biftu, T.; Scapin, G.; Singh, S.; Feng, D.; Becker, J. W.; Eiermann, G.; He, H.; Lyons, K.; Patell, S.; Petrov, A.; Sinha Roy, R.; Zhang, B.; Wu, J.; Zhang, X.; Doss, G. A.; Thornberry, N. A.; Weber, A. E. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin Bioorg. Med. Chem. Lett. 2007, 17, 3384-3387
10. Gao, Y.-G.; Feng, D.; Sheridan, R. P.; Scapin, G.; Patel, S. B.; Wu, J. K.; Zhang, X.; Sinha Roy, R.; Thornberry, N. A.; Weber, A. E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3877-3879
11. Biftu, T.; Qian, X.; Chen, P.; Feng, D.; Scapin, G.; Gao, Y-G; Cox, J.; Sinha-Roy, R.; Eiermann, G.; He, H.; Lyons, K.; Salituro, G.; Patel, P.; Petrov, A.; Xu, F.; Xu, S.; Zhang, B.; Caldwell, C.; Wu, J. K.; Weber, A. E. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2 R,3 S,5 R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2, 6-dihydropyrrolo(3,4- c)pyrazol-5(4 H)-yl)tetrahydro-2 H -pyran-3-amine Bioorg. Med. Chem. Lett. 2013, 23, 5361-5366
12. Miyazaki, H.; Tagawa, M. Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs Exp. Anim. 2002, 51, 465-475
13. Rosenblum, J. S.; Kozarich, J. W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery Curr. Opin. Chem. Biol. 2003, 7, 496-504
14. Collins, P. J.; McMahon, G.; O'Brien, P.; O'Connor, B. Purification, identification and characterisation of seprase from bovine serum Int. J. Biochem. Cell Biol. 2004, 36, 2320-2333
15. Abbott, C. A.; Yu, D. M.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 Eur. J. Biochem. 2000, 267, 6140-6150
16. Scanlan, M. J.; Raj, B. K.; Calvo, B.; Garin-Chesa, P.; Sanz-Moncasi, M. P.; Healey, J. H.; Old, L. J.; Retting, W. J. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers Proc. Natl. Acad. Sci.U.S.A. 1994, 91, 5657-5661
17. Olsen, C.; Wagtmann, N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV Gene 2002, 299, 185-195
18. Lankas, G. R.; Leiting, B.; Roy, R. S.; Wiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryon, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9 Diabetes 2005, 54, 2988-2944
19. Conarello, S. L.; Li, Z.; Ronan, J.; Sinha Roy, R.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6825
20. Gantz, I.; Chen, M.; Mirza, A.; Suryawanshi, S.; Davies, M. J.; Goldstein, B. J. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus. Presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), Berlin, Germany, October 2012; Abstract 101 (Clinical Research, Metabolism, Merck Research Laboratories).